Jurgen Lehmberg

05/2024/TT-BYT _New Vietnam MOH Circular on Price Negotiation for Medical Products (Officially issued) The Ministry of Health of Vietnam issued Circular 05/2024/TT-BYT on May 14, 2024, detailing the procedures for negotiating new prices for medicines, medical devices, and testing supplies. Key Points: - The circular applies to essential products listed on national inventories. - Price negotiations will consider the product's value, cost, and current market prices. - The newly negotiated prices will be updated in the national price lists. Source: https://lnkd.in/dRwGMBfV #Vietnam #MOH #Healthcare #Negotiation #Pricing #Medicines #MedicalDevices

154

3 Kommentare

【NEWS UPDATES】🔬🤝Huadong Medicine, a prominent pharmaceutical company, has released its annual report for 2023, showcasing impressive financial results and significant achievements. 👏With a revenue of 40.6 billion yuan and a net profit increase of 13.59%, the company's commitment to innovation and breakthrough therapies is evident.💊🚀 In endocrinology, Huadong Medicine achieved regulatory approval for domestically produced Liraglutide and obtained dual IND approvals for HDM1002, a small molecule GLP-1 receptor agonist. Their immunology portfolio includes innovative biologics and small molecule products, with HDM3001 (QX001S) receiving market approval application acceptance for plaque psoriasis.💪💡 In oncology, Huadong Medicine advanced their ADC pipeline and secured rights to market ELAHERE®, an ADC therapy for ovarian cancer. With a strong pipeline of over 60 innovative products, Huadong Medicine is poised for continued growth and contributions to healthcare advancement.💰💊 #HuadongMedicine #AnnualReport #PharmaceuticalIndustry #Innovation #Endocrinology #Immunology #Oncology #HealthcareAdvancement https://lnkd.in/gPJSxfHs

2

Mark of Excellence Endoscopy Services: Go for AACI Platinum Medal of Certification Vietnamese Federation for Digestive Endoscopy (VFDE) was established in 2011 and there are now more than 2,000 endoscopists in Vietnam. ERCP was first performed in 1993. Currently, there are more than 15,000 cases of ERCP per year. Endoscopic Ultrasound (EUS) has been widely used since 2012, and there are about 30 EUS systems in Vietnam. Perhaps 95% of the 800,000 endoscopy procedures per year in Vietnam are straightforward diagnostic procedures. Having such common procedures, ECRI Institute put cross-contamination from flexible endoscopes on the list of the top ten technology hazards for the past 3 years – it’s a sign that cross-contamination from improperly reprocessed endoscopes remains a significant and serious concern. Reasons for Endoscope- related Infections: (1) Failure to follow established reprocessing Guidelines, (2) Inadequate cleaning, (3) Improper selection or dilution of disinfecting agents, (4) Inadequate staff training and quality assurance, (5) Failure to use proper equipment during reprocessing. AACI has developed this clinical standard based on its long experience and the most common nonconformities raised during the last 15 years in the endoscopy units all around the world. The objective of this standard is to provide guidelines for precleaning, leak-testing, cleaning, storage, high-level disinfecting, and/or sterilizing of flexible gastrointestinal (GI) endoscopes, flexible bronchoscopes, surgical flexible endoscopes (e.g., flexible ureteroscopes), and semi-rigid operative endoscopes (e.g., choledochoscopes) in health care facilities. These standards are intended to provide comprehensive information and direction for health care personnel in the processing of these devices and accessories. We know Endoscopy! https://lnkd.in/gAAKHRyv Invite all the Endoscopy service providers within healthcare organizations (Clinics/Hospitals) in Vietnam and Bangladesh to join Excellence Endoscopy Services program to achieve AACI Platinum Medal of Certification! To engage, drop a message: Dr. Karim <mzkarim@aacihealthcare.com>

2

JT and Torii Pharmaceutical Co., Ltd. announced the initial results of a Phase 3 comparative study relative to pediatric patients with atopic dermatitis in Japan treated with JTE-061(tapinarof). We will aim to submit a manufacturing and marketing application for JTE-061 cream in Japan, based on the results of this and other clinical studies. For detailed results, please refer to the press release: https://lnkd.in/g2_9jhfi #JT #Torii Pharmaceutical #Pharma #tapinarof   小児アトピー性皮膚炎患者を対象とした現在開発中のJTE-061(tapinarof)について、日本国内で実施中の第Ⅲ相臨床試験（比較試験）の速報結果を得ました。 今後、本試験の成績等をもとに、日本国内における製造販売承認申請を目指します。 詳細な速報結果については、プレスリリースをご覧ください: https://lnkd.in/gt2KMrSX

175

1 Kommentar

Hematology Market Size, Share, Trends & Competitive Analysis Global Report 2024-2032 The global Hematology Market size was valued at USD 21.30 Billion in 2024 and is projected to expand at a compound annual growth rate (CAGR) of 7.3% during the forecast period, reaching a value of USD 36.21 Billion by 2032. Read Full Report@ https://lnkd.in/dSuSDeVx Hematology is the branch of medicine concerned with the study of blood, blood-forming organs, and blood diseases. It encompasses the diagnosis, treatment, and prevention of disorders affecting these components. Hematologists specialize in understanding the intricacies of blood composition, including its cells and proteins, to diagnose conditions such as anemia, leukemia, and blood clotting disorders. They utilize laboratory tests and clinical examinations to assess blood health, guiding therapies that range from medication to transfusions. The Hematology market experiences significant growth propelled by increasing demand for advanced diagnostic technologies. Innovations in hematology testing methods drive market expansion, offering healthcare providers quicker and more accurate patient diagnoses. Additionally, rising investments in research and development enhance the efficacy of hematology instruments, fostering broader adoption across medical facilities worldwide. #HematologyMarket #BloodDisorders #MedicalInnovation #HealthcareTechnology #DiagnosticTesting #BloodDiseases #PatientCare 

1

Integrity anlytics #ISPORannual #ISPOR2024 #HEOR #Middleast #market #pharma #marketaccess #ispor #ispo2024 #ICER #economics #healthcareconsulting #pharmacoeconomics #ispor #isporeurope #healtheconomics #EvidenceGeneration #EconomicsEvaluation #Modeling #Pricingandreimbursement

3

The South Korea #Pruritus_Therapeutics_Market was #valued at US$ 288.01 million in 2023 and is estimated to surpass the market #size of US$ 428.01 million by 2032, exhibiting a #CAGR of 4.50% during the #forecast period 2024–2032. 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐎𝐮𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐅𝐫𝐞𝐞: https://lnkd.in/eDHz6Khd Driven by the #country's aging population and high healthcare expenditure, South Korea's #pruritus therapeutics market is poised for #growth. With 14.9% of the #population over 65 and a commitment to addressing chronic skin conditions, the #demand for advanced #treatment options is on the rise. The nation's robust #healthcare infrastructure and government initiatives focused on #accessibility and #affordability further fuel market expansion. 𝐓𝐨𝐩 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐬 𝐒𝐨𝐮𝐭𝐡 𝐊𝐨𝐫𝐞𝐚 𝐏𝐫𝐮𝐫𝐢𝐭𝐮𝐬 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 AbbVie Amgen GSK Huons Co., Ltd. L&H company Novartis Sanofi Yuhan Corporation #PruritusTherapeutics #SkinCare #AgingPopulation #AffordableHealthcare #ChronicSkinConditions #HealthcareInfrastructure #AdvancedTreatments #InnovativeTherapies #AccessibleCare #MarketGrowth

11

🌺 United International Pharma & Obimin Brand in the journey of women's healthcare through sponsoring activities at the 24th VFAP Conference 2024 🎉 The conference attracted nearly 3,000 delegates, featuring over 60 in-depth scientific reports presented by leading professors and experts in the field of obstetrics and gynecology from Vietnam and around the world. They shared insights on practical medical issues and highlighted contemporary topics in obstetrics and gynecology, infertility, pediatrics, and nutrition, aiming to enhance women's reproductive health treatment and care. 💗 OBIMIN is a product that provides 100% of the recommended daily intake of Iron and Folic Acid according to the guidelines of the Ministry of Health of Vietnam and the World Health Organization. 💗 OBIMIN PLUS supplements DHA/EPA to aid in the development of the brain and vision in children, and to reduce the risk of depression in mothers. 💗 These products are suitable for all stages of pregnancy: for women of reproductive age/planning to become pregnant, those who are currently pregnant, or those who are breastfeeding. #UnitedInternationalPharma #UIP #Obimin #ObiminPlus #ObiminCalcium

16

Wang Yinxiang, Chairman and CEO of Jacobio Pharma, did an exclusive interview with leading Chinese tech&business media 36氪（36kr.com. Discussing the current trend of global BD partnerships in China's biotech sector, he noted that apart from global MNCs, small to mid-size European and US biotech firms are becoming increasingly interested in original scientific breakthroughs and early-stage projects from Chinese biotech companies.These companies are willing to seek incubation pipelines in China that are both economically viable and highly innovative. Speaking about the direction for biotech R&D for 2024, Wang highlighted that conquering challenging targets will play a pivotal role in the competitive landscape of Chinese and global biotech companies. Wang believes that capital "winter" and "spring" is normal and ever-present when looking back at decades of global pharmaceutical development. "Nevertheless, the long-term pursuit of health by humankind is ever-present as well, suggesting a vast space for the development of innovative pharmaceutical companies," he said. #QMportfolio #QMhealthcare #biotech #chinabiotech #36Kr #pharmaleaders #leadership #PharmaceuticalInnovation #Jacobio #HealthcareIndustry

4

#RegUpdatesWithRegDesk 🌐 Medical Device Division of Hong Kong has updated the rollout dates for e-services of the Medical Device Information System (MDIS). Link: 👉 https://lnkd.in/gaXJ_nvU Follow: 👉 RegDesk and get daily regulatory alerts straight to your inbox. #holisticrims #RegDesk #medtech #lifescience #regulatoryupdates #regulations #innovation #HongKong #MDIS

19

[Published in April 2024] 📈 Vietnamese B2B pharmaceutical platform Buymed, known locally as Thuocsi, sees a remarkable 2x year-on-year revenue growth, hitting $76.4M in 2022 💸 Despite soaring revenues, Buymed's operating losses tripled to $15.3M due to increased administrative expenses and provisions for past obligations. 🌏 Buymed isn't just stopping at Vietnam; it's broadening its marketplace model to Cambodia and Thailand, empowering small pharmacies across Southeast Asia to access affordable drugs. 🔮 As Buymed navigates growing competition and cash flow concerns, it ventures into B2B2C franchising to enhance local drugstores' operations with advanced tech solutions. 💬 With Buymed's aggressive expansion and innovative strategies, can it redefine pharmaceutical distribution in Southeast Asia? What are the potential challenges and opportunities ahead?

1

First Subject Enrollment in GT20029 China Phase 2 Trial for Acne Suzhou, June 17, 2024-Kintor Pharmaceutical Limited (“Kintor Pharma”), announced that the Company has completed the first subject enrollment in the phase II clinical trial in China of its in-house developed androgen receptor proteolysis targeting chimera (“PROTAC”) compound GT20029 for the treatment of acne. Developed by the Company’s in-house PROTAC platform, GT20029 is the first topical PROTAC compound which has entered the phase II clinical stage worldwide. The Phase II Clinical Trial is a multi-center, randomized, double-blind, placebo-controlled study, which is designed to evaluate the efficacy, safety and pharmacokinetics of GT20029 for the treatment of acne through the adoption of GT20029 0.5% once-a-day (“QD”) and 1% QD as the drug-related dosage. The Phase II Clinical Trial involves a total of 10 clinical research centers in China, and Professor Xiang Leihong from Fudan University Huashan Hospital is the lead principal investigator. In November 2022 and February 2023, the Company respectively announced the positive top-line data for the phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (“AGA”) and acne in China (healthy subjects) and in the U.S. (healthy subjects and subjects with AGA or acne). The data demonstrated good safety, tolerability and pharmacokinetics of GT20029 in healthy subjects and subjects with AGA or acne. In April 2024, the phase II trial of GT20029 for AGA has reached the primary endpoints.

3

Important News! The Ministry of Health of Indonesia announced that CDAKB certification will be required for marketing authorization of medical device distributions through Announcement No: FR.03.01/E/884/2024, as per Article 2 of Health Ministerial Regulation No.4 of 2014. For more details on CDAKB certification, please visit our blog https://lnkd.in/dE7-aDZU #AttopolisB2B #ArqonGroup #attopolis #Internationalization #PartnerInSingapore #businessmatching #regulatoryupdate #healthcare #medtechindustry #digitalhealthcare #drugs #medicaldevices #cdakbcertification #qualitysystem #kemkes #indonesia

4